Table 6.
Preventive hepatitis C virus vaccine tested in clinical trials.
| Type of vaccine | Viral component | Adjuvant | Phase of clinical trial | Study population | Year | Reference |
|---|---|---|---|---|---|---|
| Recombinant protein | Recombinant E1 protein | Aluminum hydroxide | I | 20 healthy subjects | 2004 | [123] |
| Recombinant E1 and E2 proteins | MF59 | I | 60 healthy subjects | 2010 | [124] | |
| Recombinant core protein | ISCOMATRIX | I | 60 healthy subjects | 2009 | [125] | |
|
| ||||||
| Peptide | Five synthetic peptides derived from conserved regions of core, NS3, and NS4 proteins of HCV genotypes 1 and 2 (IC41) | Poly-L-arginine | I | 128 healthy subjects | 2006 | [126] |
| Five synthetic peptides derived from conserved regions of core, NS3, and NS4 proteins of HCV genotypes 1 and 2 (IC41) | Poly-L-arginine | I | 54 healthy subjects | 2010 | [127] | |
|
| ||||||
| Virally vectored | Human adenovirus rare serotype 6 (HADV6) and chimpanzee Ad 3 (ChAd3) expressing the HCV nonstructural proteins | — | I | 30 healthy subjects | 2012 | [128] |